Emergent BioSolutions' Q3 earnings report drives 20% surge in share price, reflecting market optimism. See why award a ...

Emergent BioSolutions raised its revenue guidance and dropped a going concern warning. Its CEO is billing this next chapter ...

Emergent BioSolutions (NYSE:EBS – Get Free Report) was upgraded by StockNews.com from a “hold” rating to a “buy” rating in a report issued on Tuesday. EBS has been the subject of several other ...

The company is not selling any securities under this prospectus and will not receive any of the proceeds from the sale of securities by the ...

My name is Chris, and I will be your conference operator today. At this time, I would like to welcome everyone to the Q3 2024 ...

Emergent BioSolutions expects a 2024 net loss of $203 million-$183 million, down from the previous loss range of $314 million ...

Avidian Wealth Enterprises LLC cut its stake in shares of Emergent BioSolutions Inc. (NYSE:EBS – Free Report) by 20.4% during ...

Emergent Biosolutions ( (EBS) ) has released its Q3 earnings. Here is a breakdown of the information Emergent Biosolutions presented to its ...

Emergent BioSolutions appointed Dr. Simon Lowry as chief medical officer and head of research and development. CureVac named ...

Shares of Emergent Biosolutions climbed after the company reported an increase in revenue and swung to a profit in the third quarter. The stock was up 28% to $11.81 in Thursday afternoon trading.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Q3 2024 Earnings Call Transcript November 6, 2024 Emergent BioSolutions Inc. beats earnings expectations. Reported EPS is ...